File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus

TitleSARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus
Authors
Issue Date2005
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2005, v. 23 n. 42, p. 4959-4968 How to Cite?
AbstractDifferent forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of neutralizing antibody response against SARS-CoV were compared using a mouse model. High IgG levels were detected in mice immunized with intraperitoneal (i.p.) recombinant spike polypeptide generated by Escherichia coli (S-peptide), mice primed with intramuscular (i.m.) tPA-optimize800 DNA vaccine (tPA-S-DNA) and boosted with i.p. S-peptide, mice primed with i.m. CTLA4HingeSARS800 DNA vaccine (CTLA4-S-DNA) and boosted with i.p. S-peptide, mice primed with oral live-attenuated Salmonella typhimurium (Salmonella-S-DNA-control) and boosted with i.p. S-peptide, mice primed with oral live-attenuated S. typhimurium that contained tPA-optimize800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide, and mice primed with oral live-attenuated S. typhimurium that contained CTLA4HingeSARS800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide. No statistical significant difference was observed among the Th1/Th2 index among these six groups of mice with high IgG levels. Sera of all six mice immunized with i.p. S-peptide, i.m. DNA vaccine control and oral Salmonella-S-DNA-control showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA, oral Salmonella-S-DNA-control boosted with i.p. S-peptide, oral Salmonella-tPA-S-DNA, oral Salmonella-tPA-S-DNA boosted with i.p S-peptide, oral Salmonella-CTLA4-S-DNA and oral Salmonella-CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of <1:20-1:160. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of ≥1:1280. The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems. © 2005 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/79306
ISSN
2014 Impact Factor: 3.624
2014 SCImago Journal Rankings: 1.740
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWoo, PCYen_HK
dc.contributor.authorLau, SKPen_HK
dc.contributor.authorTsoi, HWen_HK
dc.contributor.authorChen, ZWen_HK
dc.contributor.authorWong, BHLen_HK
dc.contributor.authorZhang, Len_HK
dc.contributor.authorChan, JKHen_HK
dc.contributor.authorWong, LPen_HK
dc.contributor.authorHe, Wen_HK
dc.contributor.authorMa, Cen_HK
dc.contributor.authorChan, KHen_HK
dc.contributor.authorHo, DDen_HK
dc.contributor.authorYuen, KYen_HK
dc.date.accessioned2010-09-06T07:53:06Z-
dc.date.available2010-09-06T07:53:06Z-
dc.date.issued2005en_HK
dc.identifier.citationVaccine, 2005, v. 23 n. 42, p. 4959-4968en_HK
dc.identifier.issn0264-410Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/79306-
dc.description.abstractDifferent forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of neutralizing antibody response against SARS-CoV were compared using a mouse model. High IgG levels were detected in mice immunized with intraperitoneal (i.p.) recombinant spike polypeptide generated by Escherichia coli (S-peptide), mice primed with intramuscular (i.m.) tPA-optimize800 DNA vaccine (tPA-S-DNA) and boosted with i.p. S-peptide, mice primed with i.m. CTLA4HingeSARS800 DNA vaccine (CTLA4-S-DNA) and boosted with i.p. S-peptide, mice primed with oral live-attenuated Salmonella typhimurium (Salmonella-S-DNA-control) and boosted with i.p. S-peptide, mice primed with oral live-attenuated S. typhimurium that contained tPA-optimize800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide, and mice primed with oral live-attenuated S. typhimurium that contained CTLA4HingeSARS800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide. No statistical significant difference was observed among the Th1/Th2 index among these six groups of mice with high IgG levels. Sera of all six mice immunized with i.p. S-peptide, i.m. DNA vaccine control and oral Salmonella-S-DNA-control showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA, oral Salmonella-S-DNA-control boosted with i.p. S-peptide, oral Salmonella-tPA-S-DNA, oral Salmonella-tPA-S-DNA boosted with i.p S-peptide, oral Salmonella-CTLA4-S-DNA and oral Salmonella-CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of <1:20-1:160. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of ≥1:1280. The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems. © 2005 Elsevier Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_HK
dc.relation.ispartofVaccineen_HK
dc.rightsVaccine. Copyright © Elsevier Ltd.en_HK
dc.subject.meshAdministration, Oralen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshAntibodies, Viral - blood - immunologyen_HK
dc.subject.meshBacterial Vaccines - administration & dosage - immunologyen_HK
dc.subject.meshEscherichia coli Proteinsen_HK
dc.subject.meshImmunization Scheduleen_HK
dc.subject.meshImmunization, Secondaryen_HK
dc.subject.meshImmunoglobulin G - blooden_HK
dc.subject.meshInjections, Intramuscularen_HK
dc.subject.meshInjections, Intraperitonealen_HK
dc.subject.meshInterferon-gamma - analysisen_HK
dc.subject.meshInterleukin-4 - analysisen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMembrane Glycoproteins - administration & dosage - genetics - immunologyen_HK
dc.subject.meshMiceen_HK
dc.subject.meshMice, Inbred BALB Cen_HK
dc.subject.meshModels, Animalen_HK
dc.subject.meshNeutralization Testsen_HK
dc.subject.meshSARS Virus - immunologyen_HK
dc.subject.meshSevere Acute Respiratory Syndrome - prevention & controlen_HK
dc.subject.meshVaccines, DNA - administration & dosage - immunologyen_HK
dc.subject.meshVaccines, Synthetic - administration & dosage - immunologyen_HK
dc.subject.meshViral Envelope Proteins - administration & dosage - genetics - immunologyen_HK
dc.titleSARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirusen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0264-410X&volume=23&spage=4959&epage=4968&date=2005&atitle=SARS+coronavirus+spike+polypeptide+DNA+vaccine+priming+with+recombinant+spike+polypeptide+from+Escherichia+coli+as+booster+induces+high+titer+of+neutralizing+antibody+against+SARS+coronavirusen_HK
dc.identifier.emailWoo, PCY:pcywoo@hkucc.hku.hken_HK
dc.identifier.emailLau, SKP:skplau@hkucc.hku.hken_HK
dc.identifier.emailTsoi, HW:hwtsoi@hkucc.hku.hken_HK
dc.identifier.emailChen, ZW:zchenai@hkucc.hku.hken_HK
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_HK
dc.identifier.authorityWoo, PCY=rp00430en_HK
dc.identifier.authorityLau, SKP=rp00486en_HK
dc.identifier.authorityTsoi, HW=rp00439en_HK
dc.identifier.authorityChen, ZW=rp00243en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.vaccine.2005.05.023en_HK
dc.identifier.pmid15993989en_HK
dc.identifier.scopuseid_2-s2.0-24644485207en_HK
dc.identifier.hkuros114672en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-24644485207&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume23en_HK
dc.identifier.issue42en_HK
dc.identifier.spage4959en_HK
dc.identifier.epage4968en_HK
dc.identifier.isiWOS:000232265200001-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridWoo, PCY=7201801340en_HK
dc.identifier.scopusauthoridLau, SKP=7401596211en_HK
dc.identifier.scopusauthoridTsoi, HW=6603822102en_HK
dc.identifier.scopusauthoridChen, ZW=35271180800en_HK
dc.identifier.scopusauthoridWong, BHL=7402023413en_HK
dc.identifier.scopusauthoridZhang, L=35274165900en_HK
dc.identifier.scopusauthoridChan, JKH=35236330300en_HK
dc.identifier.scopusauthoridWong, LP=7402092221en_HK
dc.identifier.scopusauthoridHe, W=7402007628en_HK
dc.identifier.scopusauthoridMa, C=36955474600en_HK
dc.identifier.scopusauthoridChan, KH=7406034307en_HK
dc.identifier.scopusauthoridHo, DD=7402971998en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats